Dishman's Swiss subsidiary to get nod for high potency drug
Dishman Pharmaceuticals and Chemicals'(DPCLs) today said that its Switzerland-based wholly owned subsidiary -Carbogen Amcis AG- has successfully completed USFDA Pre Approval Inspection (PAI) for a new high potency drug for a US multinational.
October 04, 2011 / 17:58 IST
Dishman Pharmaceuticals and Chemicals'(DPCLs) today said that its Switzerland-based wholly owned subsidiary -Carbogen Amcis AG- has successfully completed USFDA Pre Approval Inspection (PAI) for a new high potency drug for a US multinational.
"Our Switzerland-based subsidiary Carbogen Amcis has successfully completed USFDA PAI for a new hi potency drug for a US multinational,"DPCLs Managing Director J R Vyas said."Post this approval, we expect business of around USD 10 million per annum from our existing customers,"he said."The move will bring long term contracts to the company from US,"Dishman's CFO VVS Murthy said.Carbogen Amcis is a leading service provider, offering a portfolio of drug development and services to pharmaceutical and bio-pharmaceutical industry, at different stages of drug development.DPCL, a contract research and manufacturing major (CRAM), earlier this year had announced to undertake an exercise to recast its Swiss subsidiary, after a lower than expected performance in FY-2010-11. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
